Amylin: History and overview

Diabetic Medicine

Volumn 14, Issue SUPPL. 2, 1997, Pages

  Ludvik, B ^a   Kautzky Willer, A ^a   Prager, R ^a   Thomaseth, K ^b   Pacini, G ^b  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b Inst of Syst Sci and Biomed Eng   (Italy)

Author keywords

Amylin; Diabetes mellitus; Glucose homeostasis; Insulin resistance; Plasma amylin levels

Indexed keywords

AMYLIN;

DIABETES MELLITUS; DRUG BLOOD LEVEL; DRUG MECHANISM; GLUCOSE HOMEOSTASIS; HORMONE RESPONSE; HUMAN; HYPERINSULINEMIA; INSULIN RESISTANCE; PANCREAS ISLET BETA CELL; PROTEIN SECRETION; REVIEW; STOMACH EMPTYING;

AMYLOID; ANIMALS; DIABETES MELLITUS, TYPE 2; FEMALE; GLUCOSE; HISTORY, 20TH CENTURY; HOMEOSTASIS; HUMANS; INSULIN; MALE;

EID: 0030845575     PISSN: 07423071     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1096-9136(199706)14:2+3.0.CO;2-D     Document Type: Review

References (36)

1. Opie EL. On the relation of chronic interstitial pancreatitis to the islands of Langerhans and to diabetes mellitus. J Exp Med 1901; 5: 397-428.
2. Weichselbaum A, Stangl E. Zur Kenntnis der feineren Veränderungen des Pankreas bei Diabetes Mellitus. Wien Klin Wochenschr 1901; 14: 968-972.
3. Cooper GJS, Willis AC, Clark A, Turner RC, Sim RB, Reid KB. Purification and characterization of a peptide from amyloid-rich pancreas of type 2 diabetic patients. Proc Natl Acad Sci USA 1987; 84: 8628-8632.
4. Westermark P, Wernstedt C, O'Brien TD, Hayden DW, Johnson KH. Islet amyloid in type 2 human diabetes mellitus and adult diabetic cats contains a novel putative polypeptide hormone. Am J Pathol 1987; 127: 414-417.
5. Cooper GJS, Day AJ, Willis AC, Roberts AN, Reid KB, Leighton B. Amylin and the amylin gene. Structure, function and relationship to islet amyloid and to diabetes mellitus. Biochem Biophys Acta 1989; 1014: 247-258.
6. Westermark P, Engstrom U, Johnson KH, Westermark GT, Betsholtz C. Islet amyloid polypeptide. Pinpointing amino acid residues linked to amyloid fibril formation. Proc Natl Acad Sci USA 1990; 87: 5036-5040.
7. Pittner RA, Albrandt K, Beaumont K, et al. Molecular physiology of amylin. J Cell Biochem 1994; 55S: 19-28.
8. Betsholtz C, Christmansson L, Engstrom U, et al. Sequence divergence in a specific region of islet amyloid polypeptide (IAPP) explains differences in islet amyloid formation between species. FEBS Lett 1989; 251: 261-264.
9. Janes S, Gaeta L, Beaumont K, Beeley N, Rink T. The selection of pramlintide for clinical evaluation. Diabetes 1996; 45 (suppl 2): A865.
10. Leighton B, Cooper GJ. Pancreatic amylin and calcitonin gene-related peptide cause resistance to insulin in skeletal muscle in vitro. Nature 1988; 335: 632-635.
11. Molina JM, Cooper GJS, Leighton B, Olefsky JM. Induction of insulin resistance in vivo by amylin and calcitonin gene-related peptide. Diabetes 1990; 39: 260-265.
12. Silvestre RA, Peiro E, Degano P, Miralles P, Marco J. Inhibitory effect of rat amylin on the insulin responses to glucose and arginine in the perfused rat pancreas. Regul Pept 1990; 31: 23-31.
13. Hartter E, Svoboda T, Ludvik B, et al. Basal and stimulated plasma levels of pancreatic amylin indicate its co-secretion with insulin in humans. Diabetologia 1991; 34: 52-54.
14. Sanke T, Hanabusa T, Nakano Y, et al. Plasma islet amyloid (amylin) levels and their responses to oral glucose in type 2 (non-insulin-dependent) diabetic patients. Diabetologia 1991; 34: 129-132.
15. Ludvik B, Lell B, Hartter E, Schnack C, Prager R. Decrease of stimulated amylin release precedes impairment of insulin secretion in type 2 diabetes. Diabetes 1991; 40: 1615-1619.
16. Felig P, Wahren J, Hendler R. Influence of maturity-onset diabetes on splanchnic glucose balance after oral glucose ingestion. Diabetes 1978; 27: 121-126.
17. Ludvik B, Nolan JJ, Roberts A, et al. A noninvasive method to measure splanchnic glucose uptake after oral glucose administration. J Clin Invest 1995; 95: 2232-2238.
18. Thomaseth K, Kautzky-Willer A, Ludvik B, Prager R, Pacini G. Integrated mathematical model to assess B-cell activity during the oral glucose test. Am J Physiol 1996; 270: E522-E531.
19. O'Brien TD, Westermark P, Johnson KH. Islet amyloid polypeptide and insulin secretion from isolated perfused pancreas of fed, fasted, glucose-treated, and dexamethasone-treated rats. Diabetes 1991; 40: 1701-1706.
20. Porte D, Kahn SE. Hyperproinsulinaemia and amyloid in NIDDM: clues to etiology of islet beta cell dysfunction. Diabetes 1989; 38: 1333-1336.
21. Ludvik B, Clodi M, Kautzky-Willer A, et al. Effect of dexamethasone on insulin sensitivity, islet amyloid polypeptide and insulin secretion in humans. Diabetologia 1993; 36: 84-87.
22. Kahn SE, Verchere CB, D'Alessio DA, Cook DL, Fujimoto WY. Evidence for selective release of rodent islet amyloid polypeptide through the constitutive secretory pathway. Diabetologia 1993; 36: 570-573.
23. Ludvik B, Clodi M, Kautzky-Willer A, et al. Increased levels of circulating islet amyloid polypeptide in patients with chronic renal failure have no effect on insulin secretion. J Clin Invest 1994; 94: 2045-2050.
24. DeFronzo RA, Alvestrand A, Smith D, Hendler R. Insulin resistance in uremia. J Clin Invest 1981; 67: 563-568.
25. Akmal M, Massry SC, Goldstein DA, Fanti P, Weisz A, DeFronzo RA. Role of parathyroid hormone in the glucose tolerance of chronic renal failure. J Clin Invest 1985; 75: 1037-1044.
26. Schmitz O. Effects of physiologic and supraphysiologic hyperglycemia on early- and late-phase insulin secretion in chronically dialyzed uremic patients. Acta Endocrinol 1989; 121: 251-258.
27. Graf H, Prager R, Kovarik J, Luger A, Schernthaner G, Pinggera WF. Glucose metabolism and insulin sensitivity in patients on chronic hemodialysis. Metabolism 1985; 34: 974-977.
28. Kautzky-Willer A, Pacini G, Thomaseth K, et al. IAPP and insulin kinetics and insulin sensitivity in gestational diabetes mellitus. Diabetologia 1995; 38: A282.
29. Young AA, Jodka CM, Green DE, Gedulin BR. Inhibition of arginine-induced glucagon secretion by amylin in rats. Diabetes 1994; 44: 238A.
30. Nyholm B, Møller N, Gravholt CH, et al. Acute effects of the human amylin analog AC137 on basal and insulin-stimulated euglycemic and hypoglycemic fuel metabolism in patients with insulin-dependent diabetes mellitus. J Clin Endocrinol Metab 1996; 81: 1083-1089.
31. Gedulin BR, Jodka CM, Green DE, Young AA. Potency and effectiveness of amylin and five gut peptides on gastric emptying in rats. Diabetes 1995; 44 (suppl 1): 133A.
32. 2, amylin, cholecystokinin, and other possible regulators of nutrient uptake. Metabolism 1996; 45: 1-3.
33. Macdonald I, King P, Kong M-F, et al. Infusion of the human amylin analogue, AC137, delays gastric emptying in men with IDDM. Diabetologia 1995; 38 (suppl 1): A32.
34. Young AA, Gedulin B, Vine W, Percy A, Rink TJ. Gastric emptying is accelerated in diabetic BB rats and is slowed by subcutaneous injections of amylin. Diabetologia 1994; 38: 642-648.
35. Kolterman O, Gottlieb AB, Moyses C, Colburn W. Reduction of postprandial hyperglycemia in subjects with IDDM by intravenous infusion of AC 137, a human amylin analog. Diabetes Care 1995; 18: 1179-1182.
36. Thompson RG, Gottlieb AB, Organ K, Kolterman OG. The human amylin analogue (AC137) reduces glucose following Sustacal® in patients with type 2 diabetes. Diabetes 1995; 44 (suppl 1): 127A.